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The patient had only minor shortness of breath upon
climbing two flights of stairs, despite a left ventricular
ejection fraction of 30%. He was stable and doing well on
digoxin, diuretics, beta blockers and an angiotensin-
converting enzyme (ACE) inhibitor. However, a trouble-
some dry cough was becoming intolerable to the patient.
After discussion with him, we elected to consider a trial of
an angiotensin receptor blocker in place of his ACE
inhibitor. Accordingly, I wrote him an appropriate prescrip-
tion for an angiotensin receptor blocker for this three-
month trial. That afternoon, I received a voice-mail message
from his local pharmacy. I returned the call, fully expecting
to discuss a suggested change to another “sartan.” Instead, I
was surprised by the information that the patient’s health
care plan did not have an angiotensin receptor blocker on its
formulary. I was especially troubled because he belonged to
one of the largest health care plans in northern California. I
was told by the pharmacy that I had to call the plan’s
formulary number directly to plead my case for the change
in medication. Accordingly, I called the number. After a
series of sorting through recorded telephone prompts, I was
told that I needed to hold for the next available “pharmacy
technician.” Every 30 seconds, a recorded message assured
me that my call was important, and extolled the virtues of
the health care plan. However, a second recorded voice
occasionally told me that this was a busy time and that
maybe I ought to call back later when it might be less busy.
By now, I was determined to see this through to its
conclusion, to understand the magnitude of this pharmacy
madness.
Twenty minutes later (by the clock), a “pharmacy tech-
nician” came on the phone. After I explained the situation,
it was clear that the “pharmacy technician” had no clue
about the difference between an ACE inhibitor and an
angiotensin receptor blocker. I was told to hold while he
checked. About one minute later, he came back on the line
and I was told that I could substitute a specific angiotensin
receptor blocker (different from the one that I had pre-
scribed). When asked why that particular angiotensin re-
ceptor blocker was okay (price? efficacy? pharmacokinetics?),
but yet not on their formulary, the pharmacy technician
indicated that he didn’t know. He did give electronic
approval and told me if I called the local pharmacy back in
a few minutes, they could access the “approval.” Accord-
ingly, I did this, and the man subsequently received his
medication. The whole episode took 45 minutes to an hour
of my time to effect a simple change in my patient’s
medication schedule. Unfortunately, episodes like this are
becoming increasingly common. It is the norm to get 10 to
20 faxes a day from pharmacies asking for renewals or a
change to a different “approved” drug. Not uncommonly, I
receive letters trying to “educate me” on why, in a given
patient, I should switch from one drug to another in the
same class.
At our academic institution, the outpatient pharmacy was
closed because it lost too much money. I sit on our
Pharmacy and Therapeutics Committee, which approves
new drugs. The ONLY criterion for formulary approval in
a given class is PRICE. New drugs face an incredible barrier
to being approved unless they are cheaper. There is a
circulating pharmacy SWAT team whose goal is to reduce
inpatient pharmaceutical costs in specific areas.
Patients also contribute to pharmacy madness. Fre-
quently, I need to write two prescriptions for the same
medications, so that the patient can send one of them to a
mail order pharmacy. Depending on the particulars of their
pharmacy charges or reimbursement plan, patients ask me
to write prescriptions for all of their OTC medications. The
price of medications prompts some patients who have
difficulty paying for medicine to ask (and sometimes beg) to
receive free samples, and as many as possible. When I write
prescriptions for multiple medications for elderly patients, I
have grave concerns about their compliance and their ability
to pay for the medications.
In reviewing all of the above, I believe that PHAR-
MACY MADNESS has gone too far. In order to restore
rationality to this process, it seems to me that certain
principles need to be considered:
c Economics is the underlying driving force. Thus, phar-
maceutical companies need to re-think their pricing of
drugs. Many countries have price controls on pharmaceu-
tical products. It is estimated that Americans overpaid
$16 billion in 1998 on a total bill of $120 billion.
c Physicians should have an opportunity to prescribe ap-
propriate medications for their patients.
c Health plans need to remove hassle factors and bureau-
cratic disincentives as ways to control prescribing pat-
terns.
c The whole process needs to be simplified and as uniform
as possible.
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c Special considerations need to be available for certain
groups such as the poor and the elderly.
Sorry, I had other principles to discuss, but I have to go.
I have to phone a pharmacy about a “simple” medication
change.
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